Oncology

Rural–urban disparities in prostate cancer outcomes are relatively clear. This study describes patient care experiences among rural and urban patients, as well as how they impact outcomes. Patients who live in rural areas tend, on average, to have poor access to healthcare. As a result, they tend to exhibit worse outcomes, and to have lower...

Despite the lack of pigmentation, people with vitiligo are at less risk for getting skin cancer, possibly due to increased rates of DNA repair, according to this study. A 2023 study published in the Journal of Investigative Dermatology found that skin mutations were more common in the sun-exposed areas of skin with vitiligo (lesional) than...

Prostate cancer disparities have been well documented, and this study analyzes the way they manifest in the emotional and psychosocial lives of patients who have already undergone treatment, as well as their partners. Disparities in prostate cancer outcomes are caused by a variety of factors and result in a variety of different effects, including effects...

Black men have historically faced worse outcomes from prostate cancer, and this study provides a meta-analysis of past research on this topic in order to discuss ways to move forward. Prostate cancer is the most common type of cancer diagnosed in men in the United States. Although there have been advancements made in the screening...

Darolutamide was well-tolerated by Black/African-American patients, and similar safety profiles were observed across the overall trial group. Prostate cancer (PC) is the most common cancer among men in the United States (US) and is the world’s second most common cancer after lung cancer. Furthermore, PC is associated with a high incidence and mortality rate in...

Long-chain omega-3 fatty acid (LCn3) with MAG-EPA improves urinary irritation and bowel function in patients treated with radical prostatectomy. Prostate cancer is a highly prevalent cancer that can negatively affect patients’ quality of life. Radical prostatectomy is a common treatment for intermediate- to high-grade prostate cancer, but it often has side effects such as sexual...

This study describes a deep learning algorithm model that facilitates accurate prediction of grading and staging of renal clear cell carcinoma and also promotes the optimization of individualized treatment plans. Deep learning algorithms were used to develop a model that allows the prediction of the grading and staging of renal clear cell carcinoma to facilitate...

Individuals with poor- or intermediate-risk advanced sarcomatoid renal cell carcinoma may benefit from better first-line treatment outcomes with nivolumab and ipilimumab than with sunitinib.  Patients suffering from advanced sarcomatoid renal cell carcinoma (sRCC) have poor prognostic outcomes and limited treatment options. The first-line treatment of sRCC comprises nivolumab with ipilimumab (NIVO+IPI), which has greater efficacy...

This study reports that C-reactive protein levels at baseline and after treatment may contribute to predicting the therapeutic efficacy of avelumab plus axitinib in patients suffering from advanced renal cell carcinoma. C-reactive protein (CRP) is an important predictive and prognostic marker in the case of advanced renal cell carcinoma (aRCC). In this clinical trial, the...